Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dimerix Limited ( (AU:DXB) ) has shared an update.
Dimerix Limited announced the quotation of 12,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB, effective April 2, 2025. This move is part of the company’s strategic efforts to enhance its financial flexibility and support its ongoing research and development initiatives, potentially impacting its market positioning and stakeholder interests positively.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on the development of innovative therapies for unmet medical needs. The company is primarily engaged in the research and development of pharmaceutical products, with a market focus on addressing complex diseases.
YTD Price Performance: 22.06%
Average Trading Volume: 2,439,878
Technical Sentiment Signal: Sell
Current Market Cap: A$232.1M
For detailed information about DXB stock, go to TipRanks’ Stock Analysis page.